Elastase Mediated Pulmonary Vascular Disease. Elastase

Similar documents
Research article. Department of Pharmacology and Toxicology, Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia, USA.

Pulmonary vascular remodelling: causes, mechanisms and consequences

Update On Current Concepts And Treatment Of Pulmonary Hypertension

Familial PAH. Genetics and pulmonary arterial hypertension. PAH and mutations in the bone morphogenetic protein type II receptor (BMPR-II)

Endothelial cell processes: proliferation

Navneet K. Dhillon, Ph.D. Division of Pulmonary and Critical Care University of Kansas Medical Center

Η παθοφυσιολογία και η κλινική ταξινόμηση. της πνευμονικής υπέρτασης

Pulmonary Arterial Hypertension: Biomarkers and Treatment

Current and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06

Supplementary Figure 1. TNFα reduces BMPR-II protein and mrna expression via NF-кB/RELA. (a and b) Representative immunoblots of BMPR-II in human

Pulmonary Hypertension in 2012

Clinical Commissioning Policy: Selexipag in the treatment of Pulmonary Arterial Hypertension

Pulmonary Hypertension: Classification

Role of Alpha-lipoic acid(ala) and statin in vascular smooth muscle cell proliferation

Prevalence of Insulin resistance in Pulmonary arterial hypertension patients

Vascular disease, a leading cause of mortality, represents

Supplementary Figure 1:

ACTRIIA-Fc rebalances BMP and activin/tgf-β signaling to attenuate experimental pulmonary hypertension

SUPPLEMENTARY INFORMATION

Basic Science in Transplantation. Greg Hirsch Atlantic Transplant Centre Dalhousie/CDHA

Clinical Commissioning Policy Proposition: Selexipag in the treatment of Pulmonary Arterial Hypertension

Leptin deficiency suppresses progression of atherosclerosis in apoe-deficient mice

Sotatercept PULSAR Phase 2 PAH Webinar. March 28, 2018

MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH)

Molecular pathogenesis of pulmonary arterial hypertension

JP Morgan Healthcare Conference. January 8, 2007

In Vivo Models and Cell Delivery for Lung Indications NO DISCLOSURES

Chapter. Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension

Case Study Investigation (CSI) Diagnosis and Management of Pulmonary Arterial Hypertension Case Review Monograph. editor

AVF Prevalence. Local elastase to aid fistula maturation. I have nothing to disclose

Disclosure Statement. Objectives. Novel Therapies for Vascular Access Dysfunction: OptiflowDevice, Gene Therapy, and Sirolimus Wrap 2/29/2012

FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension

Update on Pulmonary Diseases. Jeffrey Lessar, MD

ADCIRCA (tadalafil) The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

Targeting nanoparticles to degenerated elastin: A new pathway to deliver drugs for pulmonary and cardiovascular diseases

Endocannabinoid-activated Nlrp3 inflammasome in infiltrating macrophages mediates β- cell loss in type 2 diabetes

Tolerance 2. Regulatory T cells; why tolerance fails. Abul K. Abbas UCSF. FOCiS

renoprotection therapy goals 208, 209

Innate Immunity in Atherosclerosis

III. Results and Discussion

CONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION

Diabetes and Inflammasomes in the Bladder

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

Adipose Tissue as an Endocrine Organ. Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University

Disclosure Information:

Pulmonary veno-occlusive disease

Hypoxia-induced pulmonary vascular remodeling: a model for what human disease?

Title: Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events

REVATIO (sildenafil)

Effectively treating patients with pulmonary hypertension: The next chapter. Lowering PAP will improve RV function in PH

Supplementary Figures

Crosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea

INFLAMMATION. 5. Which are the main phases of inflammation in their "sequence": 1. Initiation, promotion, progression.

A class of genes that normally suppress cell proliferation. p53 and Rb..ect. suppressor gene products can release cells. hyperproliferation.

Remodeling the failing heart: : the biology and future treatment options

Sense (supply of O 2 and demand for fuel) execute DIE LIVE. The metabolic basis of PAH vascular remodeling and cancer. The Republic, Plato 3/14/2009

Anti-inflammatory properties of SM04690, a small molecule inhibitor of the Wnt pathway as a potential treatment for knee osteoarthritis

Supplementary Figure S1 Enlarged coronary artery branches in Edn1-knockout mice. a-d, Coronary angiography by ink injection in wild-type (a, b) and

Pulmonary hypertension: updating a mysterious disease

Role of Inflammatory and Progenitor Cells in Pulmonary Vascular Remodeling: Potential Role for Targeted Therapies. Traditional Hypothesis Stress

T Cell Effector Mechanisms I: B cell Help & DTH

Supplemental Figure 1

pulmonary artery vasoreactivity in patients with idiopathic pulmonary arterial hypertension

Blood Vessel Mechanics

Neuroprotective properties of GLP-1 - a brief overview. Michael Gejl Jensen, MD Dept. Of Pharmacology, AU

Pulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine

PDE5 INHIBITOR POWDERS Sildenafil powder, Tadalafil powder

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Basic Mechanisms of Atherosclerosis and Plaque Rupture: Clinical Implications

Effects of the angiotensin II type-1 receptor antagonist telmisartan on endothelial activation induced by advanced glycation endproducts

Hypertension and diabetic nephropathy

Mesenchymal Stem Cells to Repair Vascular Damage after Chemotherapy: Past, Present and Future

Growth Factor Circuitry in Vascular Morphogenesis. Lung Development

Noncirrhotic Portal Hypertension and Pathology of the Sinusoids. Ian R. Wanless Department of Pathology Dalhousie University Halifax, Canada

Enhancing the Clinical Activity of HER2/neu Specific T Cells. William Gwin, MD Internal Medicine, Resident University of Washington

Supplementary Figure 1. EC-specific Deletion of Snail1 Does Not Affect EC Apoptosis. (a,b) Cryo-sections of WT (a) and Snail1 LOF (b) embryos at

Successful completion of Phase I clinical trial of AMPK activator O304

Biomarkers in Lung Diseases: from Pathogenesis to Prediction. to New Therapies CALL FOR PAPERS


Pulmonary hypertension; does gender matter?

ESC Congress August 2011 Paris France. VEGFs and the angiogenic paradox in diabetic patients

NEDD9 is Upregulated by Hypoxia in Human Pulmonary Artery Endothelial Cells Selectively and Modulates Platelet-Endothelial Adhesion

Pathophysiology of COPD 건국대학교의학전문대학원

Tissue repair. (3&4 of 4)

Πνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ

Cell Quality Control. Peter Takizawa Department of Cell Biology

HMGB1-TLR4 Interactions: Mediators of Kidney Lung Crosstalk?

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension

Follow-up of the CUPID Gene Therapy Trials

4/14/2010. Pulmonary Hypertension: An Update. Tim Williamson, MD, FCCP. University of Kansas Hospital. Normal Physiology

T Cell Activation, Costimulation and Regulation

Progesterone responsiveness is not downregulated in adenomyosis.

DOI: /CIRCULATIONAHA

PULMONARY HYPERTENSION

Lung diseases of Vascular Origin. By: Shefaa Qa qqa

ADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION

Spleen. mlns. E Spleen 4.1. mlns. Spleen. mlns. Mock 17. Mock CD8 HIV-1 CD38 HLA-DR. Ki67. Spleen. Spleen. mlns. Cheng et al. Fig.

PVDOMICS. Study Introduction. Kristin Highland, MD Gerald Beck, PhD. NHLBI Pulmonary Vascular Disease Phenomics Program

The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations

Transcription:

PPH Newborn Autoimmune Heart defect Lung abnormality Pathology of Pulmonary Arterial Hypertension () Endothelial and Smooth Muscle Dysfunction Liver disease portal hyper. Pulmonary Hypertension Infectious: HIV, schistosomiasis? Sickle cell Substance abuse Normal PA Endothelial Cell (PAEC) PASMC proliferation EC apoptosis Idiopathic PA Smooth Muscle (PASMC) Degradation of Elastin Precedes & Associates with Severe Pulmonary Vascular Changes Mediated Pulmonary Vascular Disease Normal PA PA w/ Neointimal Lesion Endo. cell first casualty Endo. injury Serum leak Degradation of elastin Release of growth factors muscularization SMC Migration Loss of elastin: Increases vascular stiffness Promotes SMC proliferation and obliterative changes Leads to vulnerability of the distal microcirculation Loss of arteries Apoptosis Activity Progression of : Inhibition of Reverses Pathology Inhibitors (EI)Reverse PVD Induced by Toxin, in Rats Growth Factors Metallo- proteinases Day 21 norx 1K=EI Pro- inflammatory elastin peptides Tenascin-C SMC Progression GF receptor activation cell survival SMC Apoptosis Regression Veh Kyle Cowan, Nat Med. 2 M249=EI 1

Activity Induces PA Hypertension Growth Factor Receptor Blockade (PKI166) Reverses Induced PA Hypertension Growth Factors SMC Progression Metallo- proteinases Pro- inflamm peptides Tenascin-C GF receptor activation cell survival SMC Apoptosis Regression Mean PAP (mmhg) 6 4 3 2 1 (n=8-13) p<.1 vs Vehicle * Saline Vehicle PKI166 Sandra Merklinger, Circulation, 2 8 6 RVH RV/(LV+S) 4 (%) 2 * Saline Vehicle PKI166 Blockade with Imatinib Beneficial in Patients with Very High Pulmonary Vascular Resistance -Induced Medial Hypertrophy vs. Neointimal Formation in Clinical Tissue QuickTime and a decompressor are needed to see this picture. Clincal Ghofrani et al: AJRCCM, 21..n = 9-129 per group Needed: a rodent model of PA neointimal lesions S1A4(Mts-1) 1) Over-expressing expressing Mouse has Advanced Neointimal Lesions Hypothesis: Virus-Induced Degrades Susceptible Elastin & Released Elastin Peptides & GF Cause Neointima S1A4 mouse Wild Type mouse Wild Type S1A4 O/E MHV68 infection A. Susceptibility of elastin to degradation B. Heightened elastase activity Smooth Muscle Cell S1A4 is highly expressed in neointimal lesions of patients (Greenway et al., 24). Elastin peptides Growth factors Neointima 2

Mutant Receptor in Idiopathic What Promotes Beneficial Response to Injury? -RII 2,4,7 -RIA + Growth Factors Promote Adverse Remodeling Ability to activate the RII receptor! Mutated BmprII in 7%familial and 2% sporadic idiopathic PH Reduced RII+ IA expression in all forms of Transcription (regulatory) factors Bone Morphogenetic Protein Signaling Prevents Adverse Remodeling RII target genes? RIA Inhibits PA SMC Growth via Circulation 27, J Clin Invest 28 Injury: mediated release of growth factors, e.g., Adiponectin receptor Dr. George Hansmann Promotes PAEC survival and neoangiogenesis Inhibits PASMC proliferation Prevent SMC proliferation Inhibits r signal Pro-proliferative perk Cell cycle inhibitors. P27,P21 A -Antagonist Antagonist Prevents the Antiproliferative Effect of -2 2 in Human PASMC Cell Number 6x1 3 4x1 3 2x1 3 *** *** vehicle -BB -2 vehicle = GW9662 (1μM) = irreversible antagonist ***p <.1 One-Way ANOVA n = 4 Agonist glitazone Reverses PA Hypertension and in -/- Insulin Resistant Mice RVSP (mmhg) 3 2 2 1 1 4w -/- -/- 4w p <.1 n = 4-64 3

Insulin Resistance is Increased in Female Patients Pulmonary Hypertension (Zamanian, Eur Resp J, 29) IR IR IR IR Event-Free Free Survival (%) Insulin Resistance Predicts Worse 6-Month 6 Event Free Survival in Females 1 8 Dr RohamZamanian, Eur Resp J, 29) Insulin Sensitive (N=3) 6 1 Insulin Resistant (N=37) Female Male 3 6 9 12 1 18 Days γ Agonist Can Rescue Dysfunctional RII Agonist glitazone Rescues Loss of Growth Inhibition With Dysfunction of RII in PA SMC receptor agonist OD (MTT).1 RII +/- Mice *** *** +.3.2 I + RII mut *** ** + Cell cycle inhibitors..1 Suppress Growth Growth Factor Growth Factor Promotes Endothelial Survival and via ß-catenin ß- n Signaling Induces Complex Formation Between Transcription Factors and β-catenin RII RI Dr. Tero-Pekka Alastalo Migration β- Dr. Vinicio de Jesus Perez J Cell Biol: 29 unpublished β- Endothelial growth target genes? 4

Signaling Induces Complex Formation Between Transcription Factors and β-catenin RII RI Can we use a known drug to improve function of the RII receptor? Nitro- fatty acids β- β- target genes